Abstract 1561P
Background
In Estonia, based on WHO data - LC accounted for 809 new cases and 669 deaths in 2020. The first stage in the implementation of screening was a feasibility pilot conducted in 2021 to provide low-dose computed tomography (LDCT) screening for high-risk groups chosen either by USPSTF 2021 smoking criteria and/or PLCOm2012norace(>1.5% cutoff). LungFlag™ (LF) is a machine learning risk score for Lung Cancer that uses EMR data as input, it was used retrospectively in the second phase to assess risk among those individuals that performed LDCT in the pilot.
Methods
The goals of the study were to evaluate whether LF can be used on existing pilot EMR Data collected, and the potential value of LF in this setting and as a potential tool to select individuals for screening. LF was run on EMR data of individuals who performed LDCT in the pilot, minimal mandatory information of age, sex and smoking status data was required. Top 5% of individuals at risk were selected by each method and performance was compared by AUC, ranking and average age of flagged individuals. Note since LF was used retrospectively performances were limited by selected cohort.
Results
Total data included 3,708 individuals classified as high-risk by either USPSTF criteria or PLCO, out of those 3,695 were included in the comparison analysis. A total of 3,444 individuals performed LDCT identifying 31 LC cases. Average smoking years were 40, over 75% classified as current smokers. LF scores were able to be calculated for all individuals. LF ranked the risk in the study population better than the PLCO model (AUC of 0.697 vs 0.674) and significantly better than USPSTF criteria. Average age of top 5% flagged individuals by LF was over 2 years younger than PLCO (68.5 vs. 71).
Conclusions
LungFlag was able to work on Estonian EMR data, based on the pilot data and follow up it outperforms PLCO in ranking individuals that were later on diagnosed with lung cancers and improved the False Positive rate, flagging younger population. External retrospective studies suggest that LF might be even a better classifier if it was allowed to independently select high-risk people for screening from the ever smokers population in Estonia in on-going basis – additional prospective data would be necessary to prove that.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Choman.
Funding
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10